EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer

Shawn J. Rice(Penn State Milton S. Hershey Medical Center), Chandra P. Belani(Penn State Milton S. Hershey Medical Center)

PLoS ONE

May 31, 2019

10.1371/journal.pone.0217657

Cited by 12

Related Papers

Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers

|Clinical Cancer Research|2007|87

Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer

|PLoS ONE|2015|61